Colorado-based Enveda, which uses AI to discover new drugs in the natural world, raised a $311M Series E at a $2B valuation, double its valuation a year ago

If you invest in biotech or drug discovery, the pace of AI-driven natural product development is accelerating rapidly.

Colorado-based biotech startup Enveda has successfully raised $311 million in a Series E funding round, valuing the company at $2 billion. This valuation represents a doubling of Enveda's worth compared to the previous year. The funding round was led by Catalio Capital Management and included participation from Iconiq and other investors. Enveda utilizes artificial intelligence to discover novel drug candidates derived from natural sources like plants and microbes, aiming to accelerate the drug discovery process. Founded in 2019 by Viswa Colluru, a former Recursion Pharmaceuticals employee, the company is actively advancing several AI-discovered drug candidates into human clinical trials. These candidates are being tested for conditions such as severe skin disorders and for maintaining weight loss post-GLP-1 treatment.

The substantial funding and doubled valuation for Enveda signal a strong market appetite for AI-powered drug discovery, particularly those leveraging natural product pipelines. This trend suggests a growing confidence among investors in the potential of AI to unlock novel therapeutics from untapped biological sources. Enveda's progression of multiple candidates into clinical trials, targeting significant unmet needs like weight management and severe skin conditions, underscores the practical application and validation of this approach.

This development affects companies seeking to either emulate Enveda's model or compete for talent and capital in the AI biotech space. The success also puts pressure on traditional pharmaceutical companies to accelerate their own AI integration and explore natural product libraries more aggressively. Investors will likely scrutinize other AI drug discovery firms for similar clinical progress and robust natural sourcing strategies going forward.